Episode SummaryIn this episode, Georgie Kovacs, founder of Fempower Health, unpacks the recent FDA hearing on SSRI use during pregnancy—an emotionally charged and complex conversation that brought together OB-GYNs, psychiatrists, pharmacologists, and advocates.Drawing on over 25 years in healthcare consulting and six years interviewing global women's health leaders, Georgie offers a balanced, deeply informed analysis of the real conversation that took place—beyond the headlines and controversy.This wasn’t just a debate about antidepressants in pregnancy. It was a wider reckoning with how we define mental health, how we treat it, and the pressures facing clinicians and patients in a fragmented system. From risk-benefit tradeoffs and informed consent to how “depression” is diagnosed and operationalized, this episode explores what was said, what was missing, and what we need next.Whether you're a woman seeking clarity or a clinician striving to provide the best care, this episode breaks it all down.Discussion Points What actually happened at the FDA panel on SSRIs and pregnancy?Are SSRIs overprescribed—or unfairly stigmatized—during pregnancy?Is "depression" too broad of a diagnosis?How do mental health diagnoses affect treatment decisions for pregnant women?Why is informed consent inconsistent in SSRI prescribing?What are the long-term risks of untreated maternal depression?Are OB-GYNs expected to manage too much—including mental health?How does limited access to psychiatrists shape treatment options?What does better mental healthcare look like during pregnancy?Should we rethink how we integrate psychotherapy, medication, and lifestyle care?Expert Backgrounds MentionedOB-GYNs treating pregnant patients on SSRIsPsychiatrists both prescribing and deprescribing antidepressantsAcademic researchers investigating serotonin’s effects on fetal developmentAdvocacy leaders spotlighting systemic barriers to mental health careResourcesFDA Hearing: https://www.fda.gov/patients/fda-expert-panels/fda-expert-panel-selective-serotonin-reuptake-inhibitors-ssris-and-pregnancy-07212025ACOG Response to FDA Hearing: https://www.acog.org/news/news-releases/2025/07/statement-on-benefit-of-access-to-ssris-during-pregnancySociety for Maternal-Fetal Medicine (SMFM) Statement https://www.smfm.org/news/smfm-statement-on-ssris-and-pregnancyRegulatory Focus Responds: https://www.raps.org/news-and-articles/news-articles/2025/7/fda-panel-debates-label-change-on-ssri-use-duringSTAT News Responds: https://www.statnews.com/2025/07/25/ssri-drugs-fda-review-panel-antidepressants-pregnancy/National Curriculum in Reproductive Psychiatry (NCRP) Responds: https://ncrptraining.org/press-release-ncrp-responds-to-fda-panel-on-ssri-use-in-pregnancy/🎧 Loved the episode? Here's how you can take action:1. Help others discover Fempower Health:Leave a quick review on Apple or Spotify. It’s the easiest way to support our mission and amplify women’s health voices.2. Stay connected:Follow us on LinkedIn, Instagram and

Ver todos los episodios